SCHEMBL1749277

SCHEMBL1749277

Nc1ccc(N2CCC(CNC(=O)O)C2)c(CO)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 1/20 0.40
RPS6KB1 P23443 7/20 0.39
GAA P10253 1/20 0.38
ALDH1A1 P00352 5/20 0.38
MAPT P10636 5/20 0.38
KDM4E B2RXH2 3/20 0.38
MCL1 Q07820 3/20 0.38
TDP1 Q9NUW8 3/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TSHR P16473 1/20 0.38
ALOX15 P16050 2/20 0.37
MAPK1 P28482 2/20 0.37
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
GFER P55789 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749401 0.87 MAPT (0.46) RPS6KB1GAAALDH1A1MAPTKDM4E
SCHEMBL1749217 0.86 ALDH1A1 (0.44) CHRM4RPS6KB1GAAALDH1A1MAPT
SCHEMBL1749215 0.86 ALDH1A1 (0.44) CHRM4RPS6KB1GAAALDH1A1MAPT
SCHEMBL1749230 0.86 RPS6KB1 (0.39) RPS6KB1GAAALDH1A1MAPTKDM4E
SCHEMBL1749218 0.86 ALDH1A1 (0.44) CHRM4RPS6KB1GAAALDH1A1MAPT
SCHEMBL1750584 0.85 CHRM4 (0.41) CHRM4RPS6KB1GAAMAPTKDM4E
SCHEMBL1749812 0.83 SMPD3 (0.40) RPS6KB1GAA
SCHEMBL1749814 0.83 SMPD3 (0.40) RPS6KB1GAA
SCHEMBL1750143 0.83 RBP4 (0.45) RPS6KB1GAAMAPTLPLLIPG
SCHEMBL1749694 0.80 MAPT (0.52) GAAALDH1A1MAPTKDM4EMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040220191-A1 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220191-A1 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments CYP11B2, CYP11B1, CYP1A1 CHRM4 2150/4885RPS6KB1 3306/4885GAA 1379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.